on ABIONYX (EPA:ABNX)
ABIONYX Pharma unveils its 2026 financial calendar
ABIONYX Pharma, a biopharmaceutical company specializing in innovative therapies for sepsis and critical care, has released its 2026 financial communication calendar. Based on a proprietary technology centered on apoA-I, the company continues to strengthen its market position. The calendar includes several key dates for financial updates.
The first announcements will include the cash position and an update on fourth-quarter 2025 activity, scheduled for February 26. Full-year results for 2025 will be presented on March 12. Communication will continue throughout the year with regular quarterly updates, particularly for the first and second quarters, as well as a presentation of the half-year results on September 24.
Investors and partners can expect detailed information regarding the company's financial development and performance at each indicated stage.
R. H.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all ABIONYX news